Ebb & Flow

The ability of Britain's Arakis to raise £29 million ($52 million) in a series C round has spurred some sector watchers to wonder if this will encourage a spate of investing in European companies that focus on reformulation, reprofiling, in-licensing and similar activities such as the U.S. has experienced in the last few years.

Arakis is working on new clinical uses for known drugs and drug templates. The potential advantages of this approach are the acceleration of compounds through proof-of-principle, the lowering of risk and a shorter time to market. ...